Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

Ítems similars

• TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
  per: NWCJV Donk, et al.
  Publicat: (2023-10-01)
• Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
  per: Niels W. C. J. van de Donk, et al.
  Publicat: (2024-10-01)
• P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
  per: Niels W.C.J. van de Donk, et al.
  Publicat: (2023-08-01)
• P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
  per: N. van de Donk, et al.
  Publicat: (2023-05-01)
• LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES
  per: LJ Costa, et al.
  Publicat: (2024-10-01)